Description: <p><b>α-Santalol / Sandalwood oil</b> — α-Santalol is a lipophilic sesquiterpene alcohol and major bioactive constituent of East Indian sandalwood oil from <i>Santalum album</i>. It is best classified as a natural-product small molecule / essential-oil sesquiterpenoid, with sandalwood oil functioning as a botanical mixture source rather than a single-compound drug. Standard abbreviations include α-SAN, alpha-santalol, and SAO or EISO for sandalwood album / East Indian sandalwood oil. The oncology evidence is primarily preclinical, strongest for skin, prostate, breast, and oral cancer models, with no established oncology indication.</p>
<p><b>Primary mechanisms (ranked):</b></p>
<ol>
<li>Induction of intrinsic and extrinsic apoptosis through caspase activation, PARP cleavage, mitochondrial involvement, and increased apoptotic signaling.</li>
<li>Cell-cycle blockade, especially G2/M arrest, with reported tubulin interaction and mitotic disruption in oral cancer models.</li>
<li>Suppression of AKT–survivin / IAP survival signaling, including reduced p-AKT, survivin, XIAP, PCNA, cyclin D, and CDC2 in prostate cancer models.</li>
<li>Anti-migration and anti-invasive signaling through Wnt/β-catenin inhibition in breast cancer models.</li>
<li>Anti-angiogenic signaling through VEGFR2–AKT/mTOR/p70S6K pathway suppression in prostate tumor models.</li>
<li>Autophagy modulation, including AKT–mTOR-linked autophagy in prostate cancer and autophagy/cell death effects for whole sandalwood oil in proliferating keratinocytes.</li>
<li>Skin chemopreventive modulation of UVB/chemical carcinogenesis pathways, including p53/caspase-associated apoptosis and inflammatory stress-response modulation.</li>
</ol>
<p><b>Bioavailability / PK relevance:</b> α-Santalol is a small, highly lipophilic sesquiterpene alcohol, so topical and transdermal exposure is plausible, but formal human systemic PK data are limited. Oral/transdermal use should be treated as formulation- and dose-dependent, and essential-oil exposure is not equivalent to purified α-santalol exposure.</p>
<p><b>In-vitro vs systemic exposure relevance:</b> Most anticancer cell-culture studies use micromolar α-santalol concentrations, commonly around 20–75 μM depending on model and endpoint. These levels should be considered potentially above reliably documented human systemic exposure from sandalwood oil use, so in-vitro anticancer potency should not be interpreted as clinically achievable without dedicated PK/formulation data.</p>
<p><b>Clinical evidence status:</b> Preclinical for cancer prevention/therapy. Small human and dermatology-oriented evidence exists for sandalwood album oil in non-oncology skin conditions, and one clinical-trial context appears related to oral mucositis/supportive care rather than anticancer efficacy. No approved oncology indication and no high-quality human RCT evidence for cancer treatment were identified.</p>
<h3>α-Santalol and Sandalwood Oil Mechanistic Profile</h3>
<table>
<thead>
<tr>
<th>Rank</th>
<th>Pathway / Axis</th>
<th>Cancer Cells</th>
<th>Normal Cells</th>
<th>TSF</th>
<th>Primary Effect</th>
<th>Notes / Interpretation</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>Caspase apoptosis</td>
<td>↑ caspase-3, ↑ caspase-8, ↑ caspase-9, ↑ PARP cleavage, ↓ viability</td>
<td>↔ to modest toxicity at comparable experimental windows (model-dependent)</td>
<td>R/G</td>
<td>Pro-apoptotic anticancer effect</td>
<td>Core mechanism across prostate, breast, and skin cancer models; includes intrinsic and extrinsic apoptotic signaling.</td>
</tr>
<tr>
<td>2</td>
<td>Mitochondria / MPTP</td>
<td>↑ mitochondrial apoptotic signaling, ↓ mitochondrial membrane integrity (model-dependent)</td>
<td>↔ uncertain</td>
<td>R/G</td>
<td>Amplifies apoptosis</td>
<td>Mitochondrial involvement is supported mainly through caspase-9 and apoptotic readouts; direct MPTP evidence is not as strong as apoptosis evidence.</td>
</tr>
<tr>
<td>3</td>
<td>Cell cycle and tubulin</td>
<td>↑ G2/M arrest, ↓ tubulin polymerization, ↑ mitotic arrest</td>
<td>↔ uncertain</td>
<td>G</td>
<td>Anti-proliferative cytostasis and cytotoxicity</td>
<td>Strong mechanistic relevance for oral cancer and skin/breast cancer models; tubulin interaction supports antimitotic classification.</td>
</tr>
<tr>
<td>4</td>
<td>AKT / survivin / IAP</td>
<td>↓ p-AKT, ↓ survivin, ↓ XIAP, ↓ PCNA, ↓ cyclin D, ↓ CDC2</td>
<td>↔ uncertain</td>
<td>G</td>
<td>Reduces survival signaling and proliferation</td>
<td>Important prostate-cancer axis; PI3K/AKT inhibition can enhance α-santalol-induced apoptosis.</td>
</tr>
<tr>
<td>5</td>
<td>Wnt / β-catenin migration</td>
<td>↓ β-catenin-linked migration and motility</td>
<td>↔ uncertain</td>
<td>G</td>
<td>Anti-migration effect</td>
<td>Best supported in cultured breast cancer cells; therapeutic relevance remains preclinical.</td>
</tr>
<tr>
<td>6</td>
<td>VEGFR2 angiogenesis</td>
<td>↓ VEGFR2 signaling, ↓ AKT/mTOR/p70S6K, ↓ tumor angiogenesis</td>
<td>↔ uncertain</td>
<td>G</td>
<td>Anti-angiogenic effect</td>
<td>Relevant to prostate tumor xenograft-type evidence; not yet clinically validated.</td>
</tr>
<tr>
<td>7</td>
<td>Autophagy / AKT-mTOR</td>
<td>↑ autophagy (context-dependent), ↓ AKT-mTOR signaling</td>
<td>↑ autophagy/cell death in proliferating keratinocytes with whole oil (context-dependent)</td>
<td>G</td>
<td>Context-dependent stress adaptation or cell death</td>
<td>Autophagy may be protective in some prostate cancer contexts; combination strategies would need caution.</td>
</tr>
<tr>
<td>8</td>
<td>ROS / oxidative stress</td>
<td>↔ limited direct cancer-specific evidence for α-santalol as a primary ROS driver</td>
<td>↔ antioxidant effects reported in non-cancer models</td>
<td>R/G</td>
<td>Secondary or context-dependent redox modulation</td>
<td>ROS is not a core anticancer mechanism unless a specific model/source directly shows ROS-dependent killing.</td>
</tr>
<tr>
<td>9</td>
<td>NRF2</td>
<td>↔ insufficient direct α-santalol cancer evidence</td>
<td>↔ uncertain</td>
<td>G</td>
<td>Not a primary assigned mechanism</td>
<td></td>
</tr>
<tr>
<td>10</td>
<td>Glycolysis / HIF-1α</td>
<td>↔ insufficient direct evidence</td>
<td>↔ insufficient direct evidence</td>
<td>G</td>
<td>No clear primary modulation</td>
<td></td>
</tr>
<tr>
<td>11</td>
<td>Radiosensitization or chemosensitization</td>
<td>↔ limited direct evidence; possible apoptosis-combination rationale only</td>
<td>↔ uncertain</td>
<td>G</td>
<td>Unproven adjunct effect</td>
<td></td>
</tr>
<tr>
<td>12</td>
<td>Clinical Translation Constraint</td>
<td>In-vitro potency may require exposure above documented human systemic levels</td>
<td>Topical irritation or sensitization possible; systemic safety data limited</td>
<td>G</td>
<td>Limits clinical interpretation</td>
<td>Major constraints are formulation, bioavailability, mixture variability, topical safety, and lack of oncology trials.</td>
</tr>
</tbody>
</table>
<p>P: 0–30 min R: 30 min–3 hr G: >3 hr</p>